

Item (vii): The name and address of the transfer agent.

OTC Corporate Stock Transfer
53 Maple Run Dr.
Jericho, NY 11753
Email: toni@transferstock.com
(t) 516-932-2080 (f) 516-932-2078

Item (viii): The nature of the issuer's business.

1. *Form of Organization.*

A Nevada Corporation.

2. *Year Issuer was organized.*

1981

3. *Fiscal Year End Date.*

Fiscal year end date is December 31.

4. *Whether the issuer (and/or any predecessor) has been in bankruptcy, receivership or any similar proceedings.*

No

5. *Any Material reclassification, merger, consolidation or purchase or sale.*

Reverse split of commons shares, 1/150, September 2004.

6. *Has the Company had any default of the terms of any note, loan, lease, or other indebtedness or financing arrangement requiring the issuer to make payments?*

No.

7. *Has the Issuer undergone any change of control?*

No.

8. *Has there been an increase in Ten (10%) Percent or more of the same class of outstanding equity securities?*

Yes, additional shares have been issued for debt converted to equity; shares have been issued to financing ongoing company operations.

9. *Describe any past, pending or anticipated stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization.*

There is a pending stock dividend of approximately 50 million common shares. The record date is April 14, 2006. The payment date is May 1, 2006.

10. *Whether the issuer has been delisted by any securities exchange or NASDAQ or deletion from the OTC Bulletin Board.*

No

11. *Whether there are any current, past, pending or threatened legal proceedings or administrative actions either by or against the issuer that could have a material effect on the issuer's business, financial condition, or operations. Whether there are any current, past or pending trading suspensions by a securities regulator. State the names of the principal parties, the nature and current status of the matters, and the amounts involved.*

None

B. Business of the Issuer. Provide a description of the Issuer's business so a potential investor can clearly understand it.

The Company

1. *Issuer's Primary and Secondary SIC Codes.*

The Primary SIC Code for the Company is 3841.

2. *Whether the Issuer has never conducted operations, is in the development stage or is currently conducting operations.*

The Company is currently conducting operations.

3. *State the names of any parent, subsidiary, or affiliate of the issuer, and describe its business purpose, its method of operation, its ownership, and whether it is included in the financial statements attached to this disclosure document.*

None

4. *The effect of existing or probable governmental regulations on the business.*

The Company does not foresee any substantial changes that could adversely affect the business of the Company at this time.

5. *An estimate of the amount spent during each of the last two fiscal years on research and development activities, and, if applicable, the extent to which the cost of such activities are borne directly by customers.*

2005: \$81,114 (Per first accounting closing)

2004: \$376,607 (Per first accounting closing)

6. *The costs and effects of compliance with environmental laws (federal, state and local).*

Not applicable

7. *Number of total employees and number of full-time employees.*

Total and full time employees: One

C. Investment Policies. For any investments that the issuer has, provide clear descriptions of the investments, any restrictions or impairments the investments may have and the policies used to value and/or depreciate such assets from a financial and tax perspective. State whether there are any limitations of the percentage of assets which may be invested in any one investment, or type of instrument, and indicate whether such policy may be changed without a vote of security holders. State whether the issuer's policy is to acquire assets primarily for possible capital gain or primarily for income. If the issuer owns any real estate, interests in real estate, mortgages or securities related to or backed by real estate, describe the issuer's policies with respect to each of the following types of investments.

1. *Investments in real estate or interests in real estate.* Indicate the types of real estate in which the issuer may invest, and describe the method (or proposed method) of operating and financing these properties. Indicate any limitations on the number or amount of mortgages that may be placed on any one piece of property.

Not Applicable

2. *Investments in real estate mortgages.* Indicate the types of mortgages and the types of properties subject to mortgages in which the issuer plans to invest. Describe each type of mortgage activity in which the issuer intends to engage, such as originating, servicing and warehousing, and the portfolio turnover rate.

Not Applicable

3. *Securities of or interests in persons primarily engaged in real estate activities.* Indicate the types of securities in which the issuer may invest, and indicate the primary activities of persons in which the issuer may invest and the investment policies of such persons.

Not Applicable

Item (ix): The nature of products or services offered.

1. Principal products or services, and their markets.

The Company has developed a microendoscope, branded, MastaScope™. This product is designed to assist breast surgeons in the observation and investigation of the interior of breast milk ducts. The microendoscope is used by physicians in cases of breast abnormalities and nipple discharge.

The Company has researched and is developing its First Warning™ System, a device designed to assist in the early detection of breast cancer. There is additional development and patient testing required to determine the products potential.

The Company has researched and is developing it OvsScope™, a microendoscope design to assist physician in the early detection of ovarian cancer. The Company has developed prototype which are currently undergoing patient testing.

2. Distribution methods of the products or services.

The MastaScope™ is being sold internationally through our sales representative that deal directly with our distributors.

3. Status of any publicly announced new product or service.

The First Warning System™ (FWS) has additional testing pending. The commencement of the testing is awaiting the modification and updating the FWS Interpretive System. The Interpretive System is the computer based software that analyzes the breast data obtained from each test patient. The Company has acceptable levels concerning specificity and sensitivity goals. The results of previous patient testing, while very encouraging and acceptable concerning false negatives, the false positives have not been within minimum acceptable levels. Management anticipates that prospective modifications to the Interpretive System could produce acceptable results.

The OvaScope™ will continue to be tested on live patients. Additional equipment has been shipped to England for the next round of testing.

4. Competitive business conditions, the issuer's competitive position in the industry, and methods of competition.

MastaScope: The principal and most major competition for Lifeline's ductoscopy product line is Polydiagnost located in Germany. The best information available, management believes they are the current world leader with an extensive product line; Another significant, prospective company in this market, is Acueity, however it has undergone a slowing of their business. The word we get is that the company is not consistently providing products to their customers.

First Warning System: The "Gold Standard" and major market leader in breast cancer screening is mammography. Currently, this screening process has significant market share. However, there are many questions about the effectiveness of this process. Public literature suggests the mammography is missing approximately one third of the cancers. There are many companies with prospective and new technologies that are in the development and testing stages. The technologies could become meaningful competitors in the early breast cancer detection market.

OvaScope: There seems to be minimal competition in this market space. However, assuming that our testing is completed and we are cleared to market, both in the US and internationally, there could be more companies entering this space.

5. Sources and availability of raw materials and the names of principal suppliers.

There are ample raw materials and vendor sources to provide Lifeline with the currently estimated quantity requirements of the products marketed and in development. Lifeline is currently seeking cost reductions in its products provided by vendors and anticipates making changes in suppliers. This information will be updated upon resolution of this matter.

6. Dependence on one or a few major customers

Currently the Company is dependent upon several significant distributors for the sale of its MastaScope™ product line.

7. Patents, trademarks, licenses, franchises, concessions, royalty agreements or labor contracts, including their duration.

The company has several issued patents and trademarks and several pending.

8. The need for any government approval of principal products or services. Discuss the status of any requested government approvals.

For the MastaScope™, Lifeline acquired a 510(k) originally owned by Saber Endoscopy. Late last year, Lifeline filed , with the FDA, its own 510(k). In addition, Lifeline has a self-certification CE, which has permitted marketing in certain countries outside the United States. Lifeline is currently preparing an application for a CE Mark, which when obtained, will permit the Company to market in those countries where a CE Mark is required.

For the First Warning System™, the Company has a 510(k) that permits testing of this developmental medical device in the United States. Upon completion of satisfactory patient testing, the 510(k) will require updating .

For the OvaScope™, the Company anticipates that upon successful of preliminary patient testing, independent clinical trials will be required to be conducted. Assuming successful results from these clinical trials, the Company will be required to submit the results to the FDA and apply for PreMarketing Approval (PMA).

Item (x): The nature and extent of the issuer's facilities. Describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership. If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The Company rents an office at an executive office facility located at 1325 Airmotive Way, Suite 175, Reno, Nevada 89502.

The Company recently closed its office and operating facility in Pompano Beach, Florida. Inventories were moved to Solos Endoscopy, Inc., Boston, MA. Solos Endoscopy will act as a fulfillment facility for the Company.

Item (xi): The name of the chief executive officer, members of the board of directors, as well as counsel, accountant and public relations consultant.

A. Officers, Directors and Advisors. The full names, business addresses, employment histories (which should list all previous employers for the past 10 years, positions held, responsibilities and employment dates), board memberships, other affiliations, and number of securities (and of which class) beneficially owned by each such person, which information must be no older than the date of this information statement, for the issuer's:

1 and 2. Executive Officers and Directors are listed below with their business address.

| <u>Name</u> | <u>Position</u> | <u>Share Ownership/Percentage</u> |
|---------------------|---------------------------|-----------------------------------|
| Jim Holmes | President and director | 33% |
| Fred Schiemann, CPA | CFO and secretary | None |
| Louis Keith | Director – vice president | > 1% |

The principal occupation and business experience during the last several years is listed below for each of the present executive officers and directors:

President: Jim Holmes

EXPERIENCE

Chief Executive Officer of Lifeline Biotechnologies, a medical device company that has developed processes for the early detection of breast and ovarian cancers. The company is presently in clinical trials. Lifeline is a public company with over 9,000 shareholders.

Chief Executive Officer of Virtual Apothecary, a distributor of nutraceutical products through physicians; President of CCMCo., a business development, merger and acquisition and investment banking consulting company which manages the Pacific-Freeport Fund. Vice President of Nature's Creations Corp., a nutraceutical company; Director, Solos Endoscopy, Inc; Director, Trendsetter Industries, Inc.

Formerly president, treasurer, chief financial officer and/or controller of various industrial companies, private and public. This includes BioRad Labs (American Stock Exchange), Harvest Industries (OTC). Vice President and General Manager of North Coast Investments. Audit staff Pricewaterhouse Coopers, international accounting and auditing firm.

PROFESSIONAL Certified Public Accountant

University of Notre Dame, Judge-Mentor Gigot Entrepreneurial Business Development program, member Irish Angels Investment Group.

Guest Speaker, San Jose State University - DeAnza College Entrepreneurial Incubator - Business Development and Business Plan Program.

Guest Lecturer, University of Nevada Reno. Business Development, Venture Capital and business plan development.

Instructor, Empire College of Commerce. Undergraduate accounting and economics.

EDUCATION

Advanced Management College, Stanford University.

Graduate studies (MBA, Accounting and CPA Review) Golden Gate University.

Bachelor of Science, San Jose State University, business and accounting.

Numerous Venture Capital Seminars; Continuing Education (CPA).

Securities Institute seminars; American Marketing Association.

Director - Vice President: Louis G. Keith, MD, Ph.D

Dr. Louis G. Keith currently is Professor of Obstetrics and Gynecology and Director of the Section of Undergraduate Education and Medical Student Affairs at Northwestern University The Feinberg School of Medicine in Chicago. He received certification by the American Board of Obstetrics and Gynecology in 1967 and commenced his academic career at The Chicago Medical School and the Cook County Hospital in 1967. He had attained the rank of Professor in the former institution and Associate Director of the Division of Obstetrics in the latter when he was asked to assume a position as professor of Obstetrics and Gynecology and Head of the Section of Medical Student Affairs at Northwestern University in 1975. He has been elected to membership and/or fellowship in numerous professional societies in the United States and overseas and has held positions of importance in several of them.

Over the years he has received 20 awards for his scientific work and achievements. In 1995 he was named "*Distinguished Alumnus*" of *The Chicago Medical School*, and in 2000 he was awarded the *Golden Officer's Cross of the Order of Merit of the Republic of Poland*. He was also inducted as a "*Knight*" in the *International Order of Smile (UNESCO)*.

Twinning has long been a major focus of Dr. Keith's research endeavors. He has spoken nationally and internationally on a wide variety of subjects related to multiple pregnancy. He is on the boards or advisory committees of numerous international and United States organizations devoted to the study of twins or the problems their families encounter. Along with a group of co-workers, Dr. Keith has published more than 150 abstracts, articles and chapters on twinning, as well as editing three definitive textbooks in the English language: *Multiple Pregnancy: Epidemiology, gestation, and Perinatal Outcome*; *Iatrogenic Multiple Pregnancy: Clinical Implications*; and *Triplet Pregnancies and Their Consequences*. All are publications of the Parthenon Publishing Group of London and New York. The volume of *Multiple Pregnancy* came out in a Second Edition in 2005 and was awarded the Book of the Year in Obstetrics and Gynecology by the British Medical Association in London.

He received his Ph.D. at the Karol Marcinkowski University of Medical Sciences in Poznan, Poland, October 2002. The title of his dissertation was "Triplet Pregnancies in Women Age 40 or More."

CFO – Secretary – Fred Schiemann, CPA

Fred V. Schiemann, CPA, 55, received his degree from the University of Illinois, Chicago Circle Campus. Additionally, he obtained his MBA in taxation from Golden Gate University, Sacramento campus. Mr. Schiemann had his own certified public accounting firm for over fourteen years, until he sold the business at the end of 1993. During his years of practice, his main areas of focus were taxation, auditing and public securities work. He has been involved with many public registrations and structuring of mergers and acquisitions. He assisted in the financing of a nutrition company that was doing in excess of \$8.5 million dollars a year in sales. Additionally, he recently assisted a nutrition company that he organized to public through a reverse merger with a pink sheet company.

Mr. Schiemann currently has established a new accounting practice in Reno, Nevada with an emphasis on public registrations, administration and consulting to small and micro-cap public companies.

He was the interim assistant CFO for American Leisure Holdings, Inc. He currently is the treasurer of Biz2Biz.Com, Powerlean USA, Web Business Relations and Interactive Health Network.

Counsel:

General Counsel – Rew Goodnow, Esq
Marshall, Hill, et. Al. Attorneys at Law
333 Holcomb Ave, Suite 300
Reno, NV 89502
(t) 775-323-1601

Securities Counsel – Robert Laskowski, Esq.
520 S.W. Yamhill, Suite 600
Portland, OR 97204-1329
(t) 503-241-0780

Accountant or Auditor - the information should clearly describe if an outside accountant provides audit or review services, state the work done by the outside accountant, describe the responsibilities of the accountant and the responsibilities of management (i.e. who audits, prepares or reviews the issuer's financial statements, etc.). The information should include the accountant's phone number and email address and a description of the accountant's licensing and qualifications to perform such duties on behalf of the issuer;

Lopez, Blevin, Bork & Associates, CPAs
2500 Wilcrest Dr., Ste 150
Houston, TX 77042

Public Relations Consultant(s)

Big Apple Consulting USA, Inc.
407-844-0444
Maguire75@hotmail.com

Any other advisor(s) that assisted, advised, prepared or provided information with respect to this disclosure documentation – the information should include the advisor(s)' telephone number and email address.

Dr. Kefah Mokbel, Princesss Grace Hospital, London England
(t) 44-79-56-807-812
Email: kefahmokbel@hotmail.com

Dr. Pedro Escobar, Cleveland Clinic, Cleveland, Ohio
(t) 216-513-1051
Email: pe052002@yahoo.com

Dr. Kevin J. Buckman, Lodi Hospital, Lodi, CA
(t) 209-610-5000
Email: buckmanrx@yahoo.com

B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses).

NONE

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities.

NONE

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the SEC, the CFTC, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated.

NONE

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended or otherwise limited such person's involvement in any type of business or securities activities.

NONE

C. Beneficial Owners. To the extent not otherwise disclosed in response to the foregoing, provide a list of the name, address and shareholdings all persons holding more than five percent (5%) of any class of the issuer's equity securities. To the extent not otherwise disclosed, if any of the above shareholders are corporate shareholders, provide the disclosure requested in this item as to person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

NONE

D. Disclosure of Certain Relationships. Describe any relationships existing among and between the issuer's officers, directors and shareholders. To the extent not otherwise disclosed, describe all relationships and affiliations among and between the shareholders and the issuer, its predecessors, its present and prior officers and directors and other shareholders.

NONE

Item (xii): Adequate disclosure of the issuer's (or its predecessor's) current financial position, which should include the most recent fiscal year and any interim quarters.

1. The most recently prepared financial statements are attached hereto as Exhibit "A" and include a balance sheet prepared on December 31, 2004, a statement of income for the year ended December 31, 2004, a statement of cash flow for the year ended December 31, 2004 and a statement of changes in stockholders' equity. The financial statements requested pursuant to this item are prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP).

SEE ATTACHED

2. The Company intends to post all future reports on the Pinksheets website every quarter to disclose the financial condition of the company and any changes that have occurred since this statement.

Yes, we do intend to post our financials on Pinksheets website every quarter.

Item (xiii): Similar financial information for such part of the 2 preceding fiscal years as the issuer or its predecessor has been in existence.

Audits for year ended December 31, 2003 and 2002

Item (xiv): Whether any quotation is being submitted or published directly or indirectly on behalf of the issuer, or any director, officer, affiliate, or any person, directly or indirectly the beneficial owner of more than 10 percent of the outstanding units or shares of any equity security of the issuer, or at the request of any promoter for the issuer, and, if so, the name of such person, and the basis for any exemption under the federal securities laws for any sales of such securities on behalf of such person. A person is presumed to be an affiliate if they own more than 10% of the stock, but may be an affiliate even if they own less stock if the facts and circumstances indicate that they are participating with the issuer in a distribution of securities with a view to raising capital for the issuer.

Not Applicable

CERTIFICATION:

I, Jim Holmes, hereby certify that I have reviewed the Information and Disclosure Statement and the Exhibits thereto, and I have full authority to sign on behalf of the Company and do hereby certify that the information contained herein is complete and presented fairly in all material respects.

Dated this 5 day of April, 2006.

Certified By: _____
Jim Holmes, CEO

FINANCIAL INFORMATION CERTIFICATION

I, Jim Holmes, do hereby certify that I was responsible for the preparation of the statements and that such statements, and the notes thereto, present fairly, in all material respects, the financial position of the issuer and the results of its operations and cash flows for the periods presented, in conformity with accounting principles generally accepted in the United States, consistently applied.

Dated this 5th day of April, 2006.

Certified By: _____
Fred Schiemann, CFO